Blood test may replace scans for some colorectal cancer patients on immunotherapy

NCT ID NCT06098560

Recruiting now Knowledge-focused Sponsor: Geneplus-Beijing Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study is looking at whether a simple blood test that tracks tumor DNA (ctDNA) can better predict how well immunotherapy is working in people with advanced colorectal cancer. Currently, doctors rely on imaging scans, which can miss cases where the cancer is actually gone. The study will follow 60 patients to see if changes in ctDNA levels match with complete responses after surgery or over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to monitor immunotherapy effectiveness in colorectal cancer, helping doctors decide on treatment without relying solely on scans.
What could go wrong: This is an observational study, not a treatment trial. It is small (60 participants) and early-stage, so results may not apply to all patients or change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.